This study successfully demonstrates the development and optimization of a novel bovine serum albumin (BSA) nanoparticle (NP) platform designed for the synchronized delivery of all-trans retinoic acid (ATRA) and curcumin (CURC) to combat glioblastoma (GBM). The gene discussed is ALB; the disease is glioblastoma.